



**Homeland  
Security**

## Medical Countermeasure II (MCM2) for Pandemic and Emerging Threats

**\*\*\*\* Note: DHS plans to recompete the IDIQ in FY 2021. \*\*\*\***

The Department of Homeland Security (DHS) Medical Countermeasure II (MCM2) contract vehicle is a DHS-wide Indefinite Delivery/Indefinite Quantity (IDIQ) contract for Relenza™ and Tamiflu® that directly supports the DHS Pandemic Influenza and Emerging Threats Countermeasures initiative. Antiviral medications have a finite shelf life, thus requiring periodic acquisition to maintain readily available antiviral inventory.

The two types of available antivirals include:

Medical Countermeasure	MCM Type	Contract Number	Contract Vehicle
Relenza™ (Zanamivir) <a href="http://www.relenza.com/">http://www.relenza.com/</a>	Antiviral	HSHQDC-15-D-00016	IDIQ with GlaxoSmithKline (GSK)
Tamiflu® (Oseltamivir)	Antiviral	HSHQDC-15-X-00160	IAA with Department of Health and Human Services (HHS) thru OHA

### Key Contract Vehicle Features:

- Streamlines the procurement process with preferred terms, volume discounts, and pre-negotiated pricing;
- Ensures accountability and readily available access to adequate supplies;
- Allows Components to issue orders directly with the vendors using these vehicles; and
- Creates a best practice to ensure contracts are in place in case of future pandemics.

Authorized Use: Antivirals purchased under the DHS-wide IDIQ contract can be used ***only during a pandemic outbreak*** (consistent with HHS Strategic National Stockpile (SNS) requirements). The antiviral medication **cannot** be dispensed for human ***seasonal*** influenza use. A national or state-specific influenza pandemic declaration by the U.S. Department of Health and Human Services or a pandemic response ordered by the Department of Homeland Security must be affirmed to allow use of the medication. These antiviral may be purchased and stockpiled in advance of, and in preparation for, a declared pandemic.

### Period of Performance (POP):

One-year base plus four, one-year options

Relenza™: 7/13/2015 – 7/12/2020

Tamiflu®: 7/21/2015 – 7/20/2020

Number of Awardees:

Two (one large business and one federal government agency)

Contractor Information:

Contract #	Vendor Name
HSHQDC-15-D-00016	GlaxoSmithKline (GSK)
HSHQDC-15-X-00160	U.S. Department of Health and Human Services